Pharma channel feed

J&J scores ap­proval for Ry­bre­vant com­bo in first-line lung can­cer, stok­ing ri­val­ry with Tagris­so

8 months ago
FDA+

Emer­gent joins broad­er ef­forts for mpox vac­cine dri­ve in Africa

8 months ago
Manufacturing

Big em­ploy­ers are spend­ing even more mon­ey on phar­ma­cy costs, dri­ven by GLP-1s and oth­er high-cost ther­a­pies, sur­vey says

8 months ago
Health Tech

J&J buys an­oth­er medtech com­pa­ny, this time pay­ing $600M up­front for Is­rael-based V-Wave

8 months ago
Deals

Lil­ly says tirzepatide kept obese and over­weight peo­ple from de­vel­op­ing di­a­betes

8 months ago
R&D

Half of IRA ne­go­ti­a­tion sav­ings to come from three drugs, Brook­ings finds

8 months ago

Pfiz­er brings In­di­an gener­ics mak­er to court over Xel­janz patent

8 months ago
Law

Liq­uidia scores on­ly ten­ta­tive ap­proval for Yutrepia due to Ty­va­so ex­clu­siv­i­ty

8 months ago
FDA+

Medicare ne­go­ti­a­tions have con­clud­ed. What's next for court cas­es against the IRA?

9 months ago
Law

FDA ap­proves As­traZeneca’s Imfinzi be­fore and af­ter lung can­cer surgery

9 months ago
FDA+

Q&A: Lykos just cut 75% of its work­force af­ter an FDA re­jec­tion. Here’s what the CEO has to say

9 months ago
People

Genen­tech dis­solves can­cer im­munol­o­gy group, and re­search ex­ec­u­tive Ira Mell­man will leave com­pa­ny

9 months ago
People

Biden ad­min­is­tra­tion touts big drug sav­ings from IRA, but con­fi­den­tial dis­counts make it im­pos­si­ble to ver­i­fy their size

9 months ago

Bavar­i­an Nordic re­turns to the spot­light as mpox out­break reach­es emer­gency state

9 months ago
Manufacturing

Up­dat­ed: Fed­er­al gov­ern­ment re­veals ne­go­ti­at­ed prices un­der In­fla­tion Re­duc­tion Act

9 months ago
FDA+

In­cyte gets an­oth­er graft-ver­sus-host dis­ease drug ap­proval, this time with part­ner Syn­dax

9 months ago
R&D
FDA+

Blue­bird's slow sick­le cell launch forces re­work of loan, putting cash run­way at risk

9 months ago
Cell/Gene Tx

Ar­row­head lays out ear­ly-stage obe­si­ty strat­e­gy, in­clud­ing new tar­get on fat-stor­ing cells

9 months ago
R&D

Gilead wins FDA ac­cel­er­at­ed ap­proval of se­ladel­par af­ter ac­quir­ing it in $4.3B deal

9 months ago
FDA+

Evotec to cut 400 work­ers and close sites, cit­ing ‘no new sig­nals of re­cov­ery’ this year

9 months ago
Manufacturing

As­traZeneca's Imfinzi, Lyn­parza com­bo ap­proved in EU for cer­tain en­dome­tri­al can­cer pa­tients

9 months ago

Lil­ly opens huge new Boston re­search cen­ter, with a fo­cus on ge­net­ic med­i­cines

9 months ago
People
R&D

Past and present FDA ad­comm mem­bers weigh in on po­ten­tial re­forms

9 months ago
FDA+

Lex­i­con cuts about 75 sales jobs to prep for drug launch ear­ly next year

9 months ago
People
First page Previous page 37383940414243 Next page Last page
A service from the Financial Times